Advisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Termination and Reestablishment
What this record is not
Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.
The Food and Drug Administration (FDA) is announcing the termination and reestablishment of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Peripheral and Central Nervous System Drugs Advisory Committee was terminated on June 4, 2026, because its charter was not renewed on or before that expiration date. The Commissioner has determined that it is in the public interest to reestablish the Peripheral and Central Nervous System Drugs Advisory Committee for 2 years from the date it is reestablished.
Abstract as published in the Federal Register.
READ THE FULL DOCUMENT
The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.
View on federalregister.gov →That is what FDA published. A free account files it on your watchlist and sends one weekly email with whatever lands next.
Create a free account